The results of a recent University of Florida study are promising for those battling late stage liver cancer.
Liver cancer is one of the deadliest cancers--in part because patients often have a chronic liver disease in addition to tumors...and it's on the rise. So UF researchers wanted to see what would happen if they combined two available treatment options.
Dr. Ron Cabrera says, "Simultaneous combination of chemoembolization and sorafenib appeared safe in a challenging group of patients with cirrhosis and a potential survival benefit."
The study was funded by a National Institutes of Health grant. Cabrera hopes that a wider study on this combination and multi disciplinary care will increase survival rates for liver cancer patients.